Atherosclerosis is a systemic disease potentially affecting any vascular bed. Several studies reported a strong association between carotid artery stenosis with coronary artery, peripheral arterial, and aortic disease. [2] [3] [4] [5] This is why all patients undergoing coronary artery bypass graft (CABG) surgery should have a carotid ultrasound for the detection of significant (>70%) carotid artery stenosis. 6 Combined heart valve and carotid artery disease is a different issue; heart valve disease may result from different pathophysiological mechanisms than carotid atherosclerosis (eg, rheumatic or degenerative disease). However, there have been reports of an association between mitral and aortic valve calcification and generalized atherosclerosis, mainly in elderly patients. 7, 8 In these patients, carotid intima media thickness (cIMT) increases in parallel with the degree of valvular calcification score. 7 Patients undergoing heart valve surgery may also have a high prevalence of vascular risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking). 9 Extrapolating from a population-based study of patients with carotid artery occlusion, 3 the vast majority of cardiovascular patients had at least 1 vascular risk factor. Optimal blood pressure and blood glucose management, smoking cessation, and lipidlowering drugs should be targets of preoperative evaluation. These are essential measures to obtain good surgical outcomes and improve perioperative mortality and morbidity rates. 10 The treatment of hypertension with b-blockers and angiotensin-converting enzyme inhibitors (ACEIs) is associated with several beneficial effects in patients undergoing CABG. There is evidence that ACEIs are effective in decreasing myocardial injury during CABG as well as the incidence of ischemic events postoperatively. 11, 12 Additionally, b-blocker therapy reduces the incidence of atrial fibrillation and is associated with improved long-term mortality rates following CABG. 13, 14 It was thus supported that, in addition to a statin and aspirin, all CABG patients should receive routine b-blocker and ACEI treatment as part of a cardioprotective strategy to reduce recurrent ischemic events. 15, 16 It was suggested that statins may reduce the progression of calcific aortic valve stenosis. [17] [18] [19] Aortic stenosis is the product of an active inflammatory process, which shares many similarities with atherosclerosis (eg, lipoprotein accumulation). 17, 20, 21 The fact that aortic stenosis progresses faster in patients with hypercholesterolemia 19 supports this hypothesis. As statins are indicated both in the management of hypercholesterolemia 22, 23 and atherosclerosis, 24, 25 it was suggested that these agents may retard the progression of aortic stenosis. Unfortunately, this effect was not confirmed in randomized controlled trials. 26, 27 Statins failed to retard the progression of aortic stenosis 26, 27 but may decrease ischemic cardiac events in these patients. 28 Statins reduce aortic valve calcium accumulation 29, 30 and the progression of biologic prosthetic aortic valve degeneration. 31, 32 Hypercholesterolemia is an independent predictor for bioprosthetic aortic or mitral valve calcification (P ¼ .02). 33 These effects hold some implications for both the conservative and the surgical management of patients with aortic valve stenosis. The extent of aortic valve calcification is a strong predictor of aortic valve stenosis. 30 Thus, by retarding this process, the progression of aortic valve stenosis could be reduced. Furthermore, the effect of statins on the progression of biologic prosthetic aortic valve degeneration 31, 32 could potentially influence the type of aortic valve prosthesis selected in patients requiring aortic valve replacement.
It was proposed that statins may have a role in the management of patients with congenital bicuspid aortic valve malformations. 33 These patients are at a higher risk of developing aortic stenosis, aortic root dilation, aortic regurgitation, aortic aneurysm, aortic dissection, and infective endocarditis. This could occur via 2 different mechanisms: (1) by reducing the progression of aortic stenosis and aortic valve calcification [17] [18] [19] 31, 32 and (2) by limiting aortic dilatation through inhibition of matrix metalloproteinases (MMPs) [34] [35] [36] and improvement of endothelial function. 37, 38 Therefore, despite the negative trials, there is a need to further investigate several types of valve pathology at different stages of progression.
Whether statin therapy has an effect on long-term morbidity and mortality rates following cardiac valve surgery was considered in a recent systematic review (28 studies and 106 660 patients). 39 The authors did not identify statin nonuse as a predictor of early or late mortality following aortic valve replacement. 39 Nevertheless, statins may improve some of the predictors of mortality identified, such as renal dysfunction [40] [41] [42] and coronary artery disease. 43, 44 Thus, it could be hypothesized that statins potentially influence mortality rates following valve surgery in an indirect way. 10, 45 Concomitant Carotid and Cardiac Valve Disease: Which Should be Managed First?
The management of concomitant carotid and cardiac valve disease is a controversial issue. 46 A recent Cochrane Database Systematic Review on the optimal management of concomitant carotid and coronary artery disease concluded that there is as yet no evidence from randomized trials to assess the benefits and risks of prophylactic carotid surgery before CABG surgery. 6 A more recent systematic review and meta-analysis showed that neurologically asymptomatic or symptomatic patients undergoing isolated cardiac surgery in the presence of an untreated carotid stenosis or occlusion faced an increased risk of procedural stroke ranging from 7.4% increasing to 9.1% (for patients with 50%-99% stenosis or occlusion and patients with 80%-99% stenosis or occlusion, respectively). 47 After excluding symptomatic patients with a history of stroke/TIA, the same incidence fell to 2.0% and 3.8% (for patients with 70%-99% and 50%-99% carotid artery stenosis, respectively). 47 Furthermore, patients with bilateral, asymptomatic 50% to 99% stenoses or a 50% to 99% stenosis and contralateral occlusion faced a 6.5% stroke risk following cardiac surgery, while the risk of death/stroke was 9.1% (3.8%-20.6%). Patients with bilateral 80% to 99% stenosis undergoing a unilateral synchronous cardiac/carotid revascularization incurred a 5.7% risk of stroke in the hemisphere ipsilateral to the nonoperated, contralateral stenosis. 47 The conclusion reached was that based on current data, there is no indication for a prophylactic carotid intervention (carotid endarterectomy or carotid artery stenting) in cardiac surgery patients with unilateral asymptomatic carotid artery stenosis. In those patients with bilateral asymptomatic carotid artery stenosis, a prophylactic intervention may be considered, but only 1% to 2% of all cardiac surgery patients would benefit from such a strategy. 47 As supported in an earlier commentary, ''carotid surgery cannot possibly lower the risk of embolization from the ascending aorta and therefore should not be referred to as a preventive measure for stroke during CABG surgery.'' 48
Conclusions
The management of patients scheduled for cardiac valve surgery who also have concomitant carotid artery disease is complex. Both conditions are associated with established vascular risk factors and may therefore coexist. Timely management of risk factors (eg, smoking cessation, management of hyperlipidemia and hypertension) and initiation of appropriate measures (eg, statins) are essential measures to improve the outcomes of these patients. Current evidence suggests that statins may not retard the progression of aortic valve stenosis. 49, 50 Nevertheless, due to the multiple beneficial effects associated with statin use, these patients should probably still be prescribed statin treatment. 51 
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